Authors : Priya Rani; Ashish Kumar Mishra

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/2wdkm8wj

Scribd : https://tinyurl.com/ycxedrks

DOI : https://doi.org/10.38124/ijisrt/26May1804

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Pioglitazone, a thiazolidinedione (TZD) and selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, exerts pleiotropic effects on lipid homeostasis that extend well beyond its primary glucose-lowering activity. In the context of the global obesity epidemic and the rising prevalence of metabolic syndrome, understanding its lipid-modifying properties is of paramount clinical importance.  Objective: This comprehensive review synthesizes current evidence on pioglitazone-mediated modulation of lipid metabolism in obese and metabolic syndrome patients, examining molecular mechanisms, clinical outcomes, hepatic effects, and safety considerations.  Methods: A systematic search of PubMed, MEDLINE, Cochrane Library, and ClinicalTrials.gov databases was conducted. Studies published between 2000 and 2024 examining pioglitazone's lipid effects, mechanisms of action, and clinical outcomes were included.

References :

1. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19(12):151. doi:10.1007/s11892-019-1270-y
2. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet. 2005;366(9493):1279-1289.
3. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA. 2008;299(13):1561-1573.
4. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321-1331.
5. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.
6. Peng XE, Hu YL, Liu C, Xu ML. Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice. PPAR Res. 2014;2014:538183.
7. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26(2):407-413.
8. Derosa G, Cicero AF. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Drug Targets. 2008;9(6):480-489.
9. Bell DS. In praise of pioglitazone: an economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. Diabetes Obes Metab. 2023;25(8):2070-2080.
10. Tavintharan S, Ong CN, Tay EL, Gu P, Fan HY, Tai ES. Effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP study). Cardiovasc Diabetol. 2013;12:53.
11. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458-2464.
12. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37(5):907-925.
13. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
14. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45(12):1661-1669.
15. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-1118.
16. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49(10):497-505.
17. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):1-8.
18. Zhang F, Lavan BE, Gregoire FM. Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res. 2007;2007:32696.
19. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47(4):507-514.
20. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289-312.
21. Tan GD, Fielding BA, Currie JM, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005;48(1):83-95.
22. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463-478.
23. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-725.
24. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-689.
25. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18(8):629-639.
26. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
27. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
28. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
29. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428.
30. Zimmet P, Alberti KG, Serrano Ríos M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol. 2005;58(12):1371-1375.
31. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104-1115.
32. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-1935.
33. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.
34. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295.
35. Moreno-Aliaga MJ, Lorente-Cebrián S, Martínez JA. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc. 2010;69(3):324-332.
36. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094-2099.
37. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-26749.
38. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37(4):693-707.
39. Yagyu H, Iida K, Imamura K, et al. Overexpression of lipoprotein lipase in osteoblasts increases cortical bone mass in mice. FASEB J. 2012;26(7):3179-3185.
40. Staels B, Auwerx J. Perturbation of developmental programmes by fibrates and thiazolidinediones: species differences and potential relevance to humans. FEBS Lett. 1998;438(1-2):19-24.
41. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest. 1996;97(11):2408-2416.
42. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-690.
43. Pappachan JM, Babu MS, Krishnagopal P, Jayaraman S. Low-dose pioglitazone improves non-alcoholic fatty liver disease in type 2 diabetes. Sci Rep. 2022;12(1):1234.
44. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with NASH and prediabetes or T2DM. Ann Intern Med. 2016;165(5):305-315.
45. Leavens KF, McKnight RA, Crabtree GS, Bhatt DL, Bhattacharya SK. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 2009;10(5):405-418.
46. Hotamisligil GS. Inflammation and metabolic disease. Nature. 2006;444(7121):860-867.
47. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-1801.
48. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104(4):503-516.
49. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695.
50. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564.
51. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72-81.
52. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
53. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40(3):419-430.
54. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with NASH and prediabetes or T2DM: a randomized trial. Ann Intern Med. 2016;165:305-315.
55. Rombouts K, Niki T, Greenwel P, et al. Atorvastatin inhibits activation of hepatic stellate cells. Lab Invest. 2003;83(6):863-873.
56. Beraza N, Marqués JM, Martínez-Ansó E, et al. Interplay between liver growth, apoptosis and autophagy in a murine model of chronic liver injury. J Hepatol. 2009;51(2):361-371.
57. Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis. N Engl J Med. 2018;379(22):2063-2074.
58. Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FXR agonist cilofexor in noncirrhotic patients with NASH. Clin Gastroenterol Hepatol. 2020;18(12):2792-2802.
59. Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38(6):1084-1094.
60. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-654.
61. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129.
62. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89(1):200-206.
63. Cali AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab. 2008;93(5):1767-1773.
64. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(6):2784-2791.
65. Miyazaki Y, Glass L, Triplitt C, et al. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;283(6):E1135-E1143.